Donor Lymphocyte Infusion to Enhance the Graft-versus-Myeloma Effect
Abstract
:1. Introduction
2. Prophylactic Setting
3. Salvage Setting
4. Prognostic Factors in Salvage Setting
5. DLI and Patterns of Disease Progression
6. Improving DLI Effects
6.1. Enhance the Immune Response
6.2. Tumor-Specific T Cells
6.3. Cancer/Testis Antigens
6.4. Novel Agents
7. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
References
- Costa, L.J.; Iacobelli, S.; Pasquini, M.C.; Modi, R.; Giaccone, L.; Blade, J.; Schonland, S.; Evangelista, A.; Perez-Simon, J.A.; Hari, P.; et al. Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation. Bone Marrow Transplant. 2020, 55, 1810–1816. [Google Scholar] [CrossRef]
- Sobh, M.; Michallet, M.; Gahrton, G.; Iacobelli, S.; van Biezen, A.; Schönland, S.; Petersen, E.; Schaap, N.; Bonifazi, F.; Volin, L.; et al. Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: Trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. Leukemia 2016, 30, 2047–2054. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mina, R.; Lonial, S. Is there still a role for stem cell transplantation in multiple myeloma? Cancer 2019, 125, 2534–2543. [Google Scholar] [CrossRef] [PubMed]
- Shah, U.A.; Mailankody, S. Emerging immunotherapies in multiple myeloma. BMJ 2020, 370, m3176. [Google Scholar] [CrossRef] [PubMed]
- Gahrton, G.; Iacobelli, S.; Garderet, L.; Yakoub-Agha, I.; Schönland, S. Allogeneic Transplantation in Multiple Myeloma-Does It Still Have a Place? J. Clin. Med. 2020, 9, 2180. [Google Scholar] [CrossRef] [PubMed]
- Malek, E.; El-Jurdi, N.; Kröger, N.; de Lima, M. Allograft for Myeloma: Examining Pieces of the Jigsaw Puzzle. Front. Oncol. 2017, 7, 287. [Google Scholar] [CrossRef] [Green Version]
- Gahrton, G.; Iacobelli, S.; Björkstrand, B.; Hegenbart, U.; Gruber, A.; Greinix, H.; Volin, L.; Narni, F.; Carella, A.M.; Beksac, M.; et al. Autologous/reduced-intensity allogeneic stem cell transplantation vs. autologous transplantation in multiple myeloma: Long-term results of the EBMT-NMAM2000 study. Blood 2013, 121, 5055–5063. [Google Scholar] [CrossRef] [Green Version]
- Tricot, G.; Vesole, D.H.; Jagannath, S.; Hilton, J.; Munshi, N.; Barlogie, B. Graft-versus-myeloma effect: Proof of principle. Blood 1996, 87, 1196–1198. [Google Scholar] [CrossRef] [Green Version]
- Lokhorst, H.M.; Schattenberg, A.; Cornelissen, J.J.; Thomas, L.L.; Verdonck, L.F. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997, 90, 4206–4211. [Google Scholar] [CrossRef]
- Kröger, N.; Badbaran, A.; Lioznov, M.; Schwarz, S.; Zeschke, S.; Hildebrand, Y.; Ayuk, F.; Atanackovic, D.; Schilling, G.; Zabelina, T.; et al. Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. Exp. Hematol. 2009, 37, 791–798. [Google Scholar] [CrossRef]
- Donato, M.L.; Siegel, D.S.; Vesole, D.H.; McKiernan, P.; Nyirenda, T.; Pecora, A.L.; Baker, M.; Goldberg, S.L.; Mato, A.; Goy, A.; et al. The graft-versus-myeloma effect: Chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation. Biol. Blood Marrow Transplant. 2014, 20, 1211–1216. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Alyea, E.; Weller, E.; Schlossman, R.; Canning, C.; Webb, I.; Doss, D.; Mauch, P.; Marcus, K.; Fisher, D.; Freeman, A.; et al. T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: Induction of graft-versus-myeloma effect. Blood 2001, 98, 934–939. [Google Scholar] [CrossRef] [Green Version]
- Gröger, M.; Gagelmann, N.; Wolschke, C.; von Pein, U.-M.; Klyuchnikov, E.; Christopeit, M.; Zander, A.; Ayuk, F.; Kröger, N. Long-Term Results of Prophylactic Donor Lymphocyte Infusions for Patients with Multiple Myeloma after Allogeneic Stem Cell Transplantation. Biol. Blood Marrow Transplant. 2018, 24, 1399–1405. [Google Scholar] [CrossRef]
- Kröger, N.; Perez-Simon, J.A.; Myint, H.; Klingemann, H.; Shimoni, A.; Nagler, A.; Martino, R.; Alegre, A.; Tomas, J.F.; Schwerdtfeger, R.; et al. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biol. Blood Marrow Transplant. 2004, 10, 698–708. [Google Scholar] [CrossRef] [Green Version]
- Kröger, N.; Shimoni, A.; Zagrivnaja, M.; Ayuk, F.; Lioznov, M.; Schieder, H.; Renges, H.; Fehse, B.; Zabelina, T.; Nagler, A.; et al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood 2004, 104, 3361–3363. [Google Scholar] [CrossRef] [Green Version]
- Van de Donk, N.W.C.J.; Kröger, N.; Hegenbart, U.; Corradini, P.; San Miguel, J.F.; Goldschmidt, H.; Perez-Simon, J.A.; Zijlmans, M.; Raymakers, R.A.; Montefusco, V.; et al. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Blood 2006, 107, 3415–3416. [Google Scholar] [CrossRef]
- Lamure, S.; Paul, F.; Gagez, A.-L.; Delage, J.; Vincent, L.; Fegueux, N.; Sirvent, A.; Gehlkopf, E.; Veyrune, J.L.; Yang, L.Z.; et al. A Retrospective Comparison of DLI and gDLI for Post-Transplant Treatment. J. Clin. Med. 2020, 9. [Google Scholar] [CrossRef]
- Badros, A.; Barlogie, B.; Morris, C.; Desikan, R.; Martin, S.R.; Munshi, N.; Zangari, M.; Mehta, J.; Toor, A.; Cottler-Fox, M.; et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001, 97, 2574–2579. [Google Scholar] [CrossRef] [Green Version]
- Peggs, K.S.; Mackinnon, S.; Williams, C.D.; D’Sa, S.; Thuraisundaram, D.; Kyriakou, C.; Morris, E.C.; Hale, G.; Waldmann, H.; Linch, D.C.; et al. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: Limited efficacy of graft-versus-tumor activity. Biol. Blood Marrow Transplant. 2003, 9, 257–265. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Salama, M.; Nevill, T.; Marcellus, D.; Parker, P.; Johnson, M.; Kirk, A.; Porter, D.; Giralt, S.; Levine, J.E.; Drobyski, W.; et al. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant. 2000, 26, 1179–1184. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lokhorst, H.M.; Wu, K.; Verdonck, L.F.; Laterveer, L.L.; van de Donk, N.W.C.J.; van Oers, M.H.J.; Cornelissen, J.J.; Schattenberg, A.V. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004, 103, 4362–4364. [Google Scholar] [CrossRef] [Green Version]
- El-Cheikh, J.; Crocchiolo, R.; Furst, S.; Ladaique, P.; Castagna, L.; Faucher, C.; Granata, A.; Oudin, C.; Lemarie, C.; Calmels, B.; et al. Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma. Exp. Hematol. 2012, 40, 521–527. [Google Scholar] [CrossRef] [PubMed]
- Montefusco, V.; Spina, F.; Patriarca, F.; Offidani, M.; Bruno, B.; Montanari, M.; Mussetti, A.; Sperotto, A.; Scortechini, I.; Dodero, A.; et al. Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation. Biol. Blood Marrow Transplant. 2013, 19, 424–428. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Greiner, J.; Götz, M.; Bunjes, D.; Hofmann, S.; Wais, V. Immunological and Clinical Impact of Manipulated and Unmanipulated DLI after Allogeneic Stem Cell Transplantation of AML Patients. J. Clin. Med. 2019, 9, 39. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kolb, H.J.; Schattenberg, A.; Goldman, J.M.; Hertenstein, B.; Jacobsen, N.; Arcese, W.; Ljungman, P.; Ferrant, A.; Verdonck, L.; Niederwieser, D.; et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995, 86, 2041–2050. [Google Scholar] [CrossRef] [Green Version]
- Collins, R.H.; Shpilberg, O.; Drobyski, W.R.; Porter, D.L.; Giralt, S.; Champlin, R.; Goodman, S.A.; Wolff, S.N.; Hu, W.; Verfaillie, C.; et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol. 1997, 15, 433–444. [Google Scholar] [CrossRef]
- Lokhorst, H.M.; Schattenberg, A.; Cornelissen, J.J.; van Oers, M.H.; Fibbe, W.; Russell, I.; Donk, N.W.; Verdonck, L.F. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: Predictive factors for response and long-term outcome. J. Clin. Oncol. 2000, 18, 3031–3037. [Google Scholar] [CrossRef]
- Ayuk, F.; Shimoni, A.; Nagler, A.; Schwerdtfeger, R.; Kiehl, M.; Sayer, H.G.; Zabelina, T.; Zander, A.R.; Kröger, N. Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma. Leukemia 2004, 18, 659–662. [Google Scholar] [CrossRef] [Green Version]
- Van de Donk, N.W.C.J.; Kröger, N.; Hegenbart, U.; Corradini, P.; San Miguel, J.F.; Goldschmidt, H.; Perez-Simon, J.A.; Zijlmans, M.; Raymakers, R.A.; Montefusco, V.; et al. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant. 2006, 37, 1135–1141. [Google Scholar] [CrossRef] [Green Version]
- Brinkman, C.C.; Rouhani, S.J.; Srinivasan, N.; Engelhard, V.H. Peripheral tissue homing receptors enable T cell entry into lymph nodes and affect the anatomical distribution of memory cells. J. Immunol. 2013, 191, 2412–2425. [Google Scholar] [CrossRef] [Green Version]
- Van der Voort, R.; Volman, T.J.H.; Verweij, V.; Linssen, P.C.M.; Maas, F.; Hebeda, K.M.; Dolstra, H. Homing characteristics of donor T cells after experimental allogeneic bone marrow transplantation and posttransplantation therapy for multiple myeloma. Biol. Blood Marrow Transplant. 2013, 19, 378–386. [Google Scholar] [CrossRef] [PubMed]
- Minnema, M.C.; van de Donk, N.W.C.J.; Zweegman, S.; Hegenbart, U.; Schonland, S.; Raymakers, R.; Zijlmans, J.M.J.M.; Kersten, M.J.; Bos, G.M.J.; Lokhorst, H.M. Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome. Bone Marrow Transplant. 2008, 41, 779–784. [Google Scholar] [CrossRef]
- Eefting, M.; de Wreede, L.C.; von dem Borne, P.A.; Halkes, C.J.M.; Kersting, S.; Marijt, E.W.A.; Putter, H.; Veelken, H.; Schetelig, J.; Falkenburg, J.H.F. Donor T-cell responses and disease progression patterns of multiple myeloma. Bone Marrow Transplant. 2017, 52, 1609–1615. [Google Scholar] [CrossRef] [Green Version]
- Shlomchik, W.D.; Couzens, M.S.; Tang, C.B.; McNiff, J.; Robert, M.E.; Liu, J.; Shlomchik, M.J.; Emerson, S.G. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999, 285, 412–415. [Google Scholar] [CrossRef]
- Duffner, U.A.; Maeda, Y.; Cooke, K.R.; Reddy, P.; Ordemann, R.; Liu, C.; Ferrara, J.L.M.; Teshima, T. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J. Immunol. 2004, 172, 7393–7398. [Google Scholar] [CrossRef]
- Mapara, M.Y.; Kim, Y.-M.; Wang, S.-P.; Bronson, R.; Sachs, D.H.; Sykes, M. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: A critical role for host antigen-presenting cells. Blood 2002, 100, 1903–1909. [Google Scholar] [CrossRef]
- Auffermann-Gretzinger, S.; Lossos, I.S.; Vayntrub, T.A.; Leong, W.; Grumet, F.C.; Blume, K.G.; Stockerl-Goldstein, K.E.; Levy, R.; Shizuru, J.A. Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients. Blood 2002, 99, 1442–1448. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Oostvogels, R.; Minnema, M.C.; van Elk, M.; Spaapen, R.M.; te Raa, G.D.; Giovannone, B.; Buijs, A.; van Baarle, D.; Kater, A.P.; Griffioen, M.; et al. Towards effective and safe immunotherapy after allogeneic stem cell transplantation: Identification of hematopoietic-specific minor histocompatibility antigen UTA2-1. Leukemia 2013, 27, 642–649. [Google Scholar] [CrossRef] [PubMed]
- Oostvogels, R.; Kneppers, E.; Minnema, M.C.; Doorn, R.C.; Franssen, L.E.; Aarts, T.; Emmelot, M.E.; Spierings, E.; Slaper-Cortenbach, I.; Westinga, K.; et al. Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients. Bone Marrow Transplant. 2017, 52, 228–237. [Google Scholar] [CrossRef] [PubMed]
- Franssen, L.E.; Roeven, M.W.H.; Hobo, W.; Doorn, R.; Oostvogels, R.; Falkenburg, J.H.F.; van de Donk, N.W.; Kester, M.G.D.; Fredrix, H.; Westinga, K.; et al. A phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma. Bone Marrow Transplant. 2017, 52, 1378–1383. [Google Scholar] [CrossRef]
- Rezvani, K.; Yong, A.S.M.; Savani, B.N.; Mielke, S.; Keyvanfar, K.; Gostick, E.; Price, D.A.; Douek, D.C.; Barrett, A.J. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood 2007, 110, 1924–1932. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kapp, M.; Stevanović, S.; Fick, K.; Tan, S.M.; Loeffler, J.; Opitz, A.; Tonn, T.; Stuhler, G.; Einsele, H.; Grigoleit, G.U. CD8+ T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT. Bone Marrow Transplant. 2009, 43, 399–410. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tyler, E.M.; Jungbluth, A.A.; O’Reilly, R.J.; Koehne, G. WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions. Blood 2013, 121, 308–317. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Binsfeld, M.; Beguin, Y.; Belle, L.; Otjacques, E.; Hannon, M.; Briquet, A.; Heusschen, R.; Drion, P.; Zilberberg, J.; Bogen, B.; et al. Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation. PLoS ONE 2014, 9, e113764. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yado, S.; Luboshits, G.; Hazan, O.; Or, R.; Firer, M.A. Long-term survival without graft-versus-host-disease following infusion of allogeneic myeloma-specific Vβ T cell families. J. Immunother. Cancer 2019, 7, 301. [Google Scholar] [CrossRef]
- Atanackovic, D.; Hildebrandt, Y.; Jadczak, A.; Cao, Y.; Luetkens, T.; Meyer, S.; Kobold, S.; Bartels, K.; Pabst, C.; Lajmi, N.; et al. Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells. Haematologica 2010, 95, 785–793. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rapoport, A.P.; Stadtmauer, E.A.; Binder-Scholl, G.K.; Goloubeva, O.; Vogl, D.T.; Lacey, S.F.; Badros, A.Z.; Garfall, A.; Weiss, B.; Finklestein, J.; et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat. Med. 2015, 21, 914–921. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lajmi, N.; Luetkens, T.; Yousef, S.; Templin, J.; Cao, Y.; Hildebrandt, Y.; Bartels, K.; Kröger, N.; Atanackovic, D. Cancer-testis antigen MAGEC2 promotes proliferation and resistance to apoptosis in Multiple Myeloma. Br. J. Haematol. 2015, 171, 752–762. [Google Scholar] [CrossRef]
- Atanackovic, D.; Arfsten, J.; Cao, Y.; Gnjatic, S.; Schnieders, F.; Bartels, K.; Schilling, G.; Faltz, C.; Wolschke, C.; Dierlamm, J.; et al. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood 2007, 109, 1103–1112. [Google Scholar] [CrossRef] [Green Version]
- Luetkens, T.; Kobold, S.; Cao, Y.; Ristic, M.; Schilling, G.; Tams, S.; Bartels, B.M.; Templin, J.; Bartels, K.; Hildebrandt, Y.; et al. Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation. Cancer Immunol. Immunother. 2014, 63, 1151–1162. [Google Scholar] [CrossRef]
- Rapoport, A.P.; Aqui, N.A.; Stadtmauer, E.A.; Vogl, D.T.; Xu, Y.Y.; Kalos, M.; Cai, L.; Fang, H.-B.; Weiss, B.M.; Badros, A.; et al. Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells. Clin. Cancer Res. 2014, 20, 1355–1365. [Google Scholar] [CrossRef] [Green Version]
- Sonneveld, P.; Avet-Loiseau, H.; Lonial, S.; Usmani, S.; Siegel, D.; Anderson, K.C.; Chng, W.-J.; Moreau, P.; Attal, M.; Kyle, R.A.; et al. Treatment of multiple myeloma with high-risk cytogenetics: A consensus of the International Myeloma Working Group. Blood 2016, 127, 2955–2962. [Google Scholar] [CrossRef]
- Maffini, E.; Storer, B.E.; Sandmaier, B.M.; Bruno, B.; Sahebi, F.; Shizuru, J.A.; Chauncey, T.R.; Hari, P.; Lange, T.; Pulsipher, M.A.; et al. Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma. Haematologica 2019, 104, 380–391. [Google Scholar] [CrossRef] [PubMed]
- Jurgensen-Rauch, A.; Gibbs, S.; Farrell, M.; Aries, J.; Grantham, M.; Eccersley, L.; Gribben, J.; Hallam, S.; Oakervee, H.; Cavenagh, J.; et al. Reduced intensity allogeneic hematopoietic stem cell transplantation is a safe and effective treatment option in high-risk myeloma patients—A single centre experience. Br. J. Haematol. 2021. [Google Scholar] [CrossRef] [PubMed]
- Gagelmann, N.; Eikema, D.-J.; de Wreede, L.C.; Rambaldi, A.; Iacobelli, S.; Koster, L.; Caillot, D.; Blaise, D.; Remémyi, P.; Bulabois, C.-E.; et al. Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): A study from the CMWP-EBMT. Bone Marrow Transplant. 2021, 56, 210–217. [Google Scholar] [CrossRef] [PubMed]
- Bruno, B.; Wäsch, R.; Engelhardt, M.; Gay, F.; Giaccone, L.; D’Agostino, M.; Rodríguez-Lobato, L.-G.; Danhof, S.; Gagelmann, N.; Kröger, N.; et al. European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma. Haematologica 2021. [Google Scholar] [CrossRef]
- Rasche, L.; Hudecek, M.; Einsele, H. What is the future of immunotherapy in multiple myeloma? Blood 2020, 136, 2491–2497. [Google Scholar] [CrossRef] [PubMed]
Study (Year) | N | Graft Type | Dose (Range), ×106 Cells/kg | Response, % | Acute GVHD, n | Survival |
---|---|---|---|---|---|---|
Alyea [12] (2001) | 14 | MRD | 10–30 | 86 | 7 | PFS: 65% 2y |
Badros [18] (2001) | 14 | MRD | 120–220 | 86 | 10 | OS: 69% 1y |
Peggs [19] (2003) | 20 | MRD/MUD | 1–100 | 50 | 3 | PFS: 30% 2y OS: 71% 2y |
Kröger [10] (2009) | 32 | MRD/MUD | 0.5–200 | 78 | 13 | PFS: 54% 5y |
Gröger [13] (2018) | 61 | MRD/MUD | 0.3–100 | 77 | 7 | PFS: 43% 8y OS: 67% 8y |
Study (Year) | N | Graft Type | Dose (Range), ×106 Cells/kg | Response, % | Acute GVHD, n | Survival |
---|---|---|---|---|---|---|
Lokhorst [9] (1997) | 13 | MRD | 1–330 | 62 | 9 | 54% 1y |
Salama [20] (2000) | 25 | MRD/MUD | 2–224 | 36 | 13 | 48% 1y |
Lokhorst [21] (2004) | 54 | MRD | 1–500 | 52 | 31 | PFS: 19m OS: 23m |
El-Cheikh [22] (2012) | 9 | MRD/MUD | 10–100 | 75 | 1 | PFS: 50% 2y OS: 69% 2y |
Montefusco [23] (2013) | 19 | MRD/MUD | 0.5–100 | 68 | 2 | PFS: 31% 3y OS: 73% 3y |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Gagelmann, N.; Kröger, N. Donor Lymphocyte Infusion to Enhance the Graft-versus-Myeloma Effect. Hemato 2021, 2, 207-216. https://doi.org/10.3390/hemato2020012
Gagelmann N, Kröger N. Donor Lymphocyte Infusion to Enhance the Graft-versus-Myeloma Effect. Hemato. 2021; 2(2):207-216. https://doi.org/10.3390/hemato2020012
Chicago/Turabian StyleGagelmann, Nico, and Nicolaus Kröger. 2021. "Donor Lymphocyte Infusion to Enhance the Graft-versus-Myeloma Effect" Hemato 2, no. 2: 207-216. https://doi.org/10.3390/hemato2020012
APA StyleGagelmann, N., & Kröger, N. (2021). Donor Lymphocyte Infusion to Enhance the Graft-versus-Myeloma Effect. Hemato, 2(2), 207-216. https://doi.org/10.3390/hemato2020012